OpenAlex
PricingAboutJobs
Log inGet started
Work

Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens

HTML PDF

Year: 2009
Type: article
Study design: Clinical Trial
Source: Annals of Oncology
DOI: 10.1093/annonc/mdn759
Authors: K.L. Blackwell, M.D. Pegram, E. Tan-Chiu, L.S. Schwartzberg, M.C. Arbushites, J.D. Maltzman, J.K. Forster, S.D. Rubin, S.H. Stein, H.J. Burstein
Institutions: Duke University, Duke Medical Center, University of California, Los Angeles, Florida Cancer Care, GlaxoSmithKline (United States), Dana-Farber Cancer Institute
Language: English

Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: lapatinib, HER2-positive breast cancer, metastatic breast cancer, trastuzumab resistance, monotherapy, tyrosine kinase inhibitors, treatment response, adverse events, rash, diarrhea, overall survival
SDG: Good health and well-being

Open Access status: bronze

Funder: GlaxoSmithKline
OpenAlex ID: W2117342140
FWCI: 14.26
Cites: 30
Cited by: 168
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms